MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413917 | Name: Ecabapide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ecabapide is a compound with antiulcer and gastroprokinetic activity. Evidence from basic studies in animal models suggests that the drug acts on peripheral mechanisms of neural control. In the stomach, ecabapide acts to suppress firing in vagal afferent nerves and thereby reduce the flow of sensory information into the dorsal vagal complex. The mechanism of action of ecabapide in suppressing discharge in vagal afferent terminals appears to mimic that of nitric oxide by stimulating formation of cGMP and activation of an inhibitory transduction cascade in the sensory fibres. In this respect the mechanism of its pro-kinetic action differs from other promoter agents. Ecabapide development has been discontinued.

Chemical Structure

Ecabapide
Ecabapide
CAS#104775-36-2

Theoretical Analysis

MedKoo Cat#: 413917

Name: Ecabapide

CAS#: 104775-36-2

Chemical Formula: C20H25N3O4

Exact Mass: 371.1845

Molecular Weight: 371.44

Elemental Analysis: C, 64.67; H, 6.78; N, 11.31; O, 17.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Ecabapide; DQ 2511; DQ-2511; DQ2511
IUPAC/Chemical Name
Benzamide, 3-((2-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-oxoethyl)amino)-N-methyl-
InChi Key
JTAGHJPZEDNHHA-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H25N3O4/c1-21-20(25)15-5-4-6-16(12-15)23-13-19(24)22-10-9-14-7-8-17(26-2)18(11-14)27-3/h4-8,11-12,23H,9-10,13H2,1-3H3,(H,21,25)(H,22,24)
SMILES Code
O=C(NC)C1=CC=CC(NCC(NCCC2=CC=C(OC)C(OC)=C2)=O)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 371.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Furuhama K. Ecabapide, a novel gastroprokinetic agent, ameliorates gastric emptying of stroke-prone spontaneously hypertensive rats (SHRSP). J Vet Med Sci. 1997 Dec;59(12):1153-5. doi: 10.1292/jvms.59.1153. PMID: 9450247. 2: Furuhama K, Wood JD. Pharmacology of the gastric pro-kinetic drug ecabapide (DQ-2511). J Pharm Pharmacol. 1997 Dec;49(12):1168-74. doi: 10.1111/j.2042-7158.1997.tb06064.x. PMID: 9466337. 3: Nakaoka M, Tsumura M, Ichikawa E, Suzuki W, Hakusui H, Nakazawa T. Identification of major biliary and urinary metabolites of ecabapide in rats. Xenobiotica. 1996 Sep;26(9):983-94. doi: 10.3109/00498259609052500. PMID: 8893045. 4: Fujimaki Y, Arai N, Inaba T. Identification of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent. Xenobiotica. 1999 Dec;29(12):1273-82. doi: 10.1080/004982599237930. PMID: 10647912. 5: Jiang W, Grundy D. Modulation of gastrointestinal afferent sensitivity by a novel substituted benzamide (ecabapide). J Auton Nerv Syst. 2000 Jan 14;78(2-3):99-108. doi: 10.1016/s0165-1838(99)00063-6. PMID: 10789688. 6: Hosokami T, Tabuchi Y, Furuhama K. [Effects of 2-(3,4-dimethoxyphenyl)ethylamine derivative (ecabapide, DQ-2511) and its metabolites on water-immersion restraint stress-induced gastric ulcers in rats]. Yakugaku Zasshi. 1995 Feb;115(2):114-9. Japanese. doi: 10.1248/yakushi1947.115.2_114. PMID: 7722878. 7: Fujimaki Y, Hosokami T, Ono K. Identification of urinary metabolites of ecabapide in rat. Xenobiotica. 1995 May;25(5):501-10. doi: 10.3109/00498259509061869. PMID: 7571723. 8: Sakai H, Ikari A, Kumano E, Takeguchi N. A cyclic GMP-dependent housekeeping Cl- channel in rabbit gastric parietal cells activated by a vasodilator ecabapide. Br J Pharmacol. 1996 Dec;119(8):1591-9. doi: 10.1111/j.1476-5381.1996.tb16077.x. PMID: 8982506; PMCID: PMC1915798. 9: Hatanaka S, Kawarabayashi K, Iseri M, Tsubokura K, Furuhama K. Enhancing effect of DQ-2511 on gastric emptying of spontaneously hypertensive rats. Life Sci. 1995;56(19):PL377-82. doi: 10.1016/0024-3205(95)00133-q. PMID: 7723581. 10: Hatanaka S, Niijima A, Furuhama K. Possible mechanisms underlying the suppression of gastric vagal afferents due to ecabapide (DQ-2511), a gastroprokinetic agent, in rats. Jpn J Pharmacol. 1997 May;74(1):105-8. doi: 10.1254/jjp.74.105. PMID: 9195305.